Phase II trial of bortezomib for patients with advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Pyrazines

abstract

  • The results of this trial suggest that bortezomib has an antitumor effect in individual patients with metastatic RCC. The small proportion of patients who achieved a partial response does not support routine use in metastatic RCC. Efforts to identify the molecular profile associated with clinical response or combination therapy with interferon alfa or other novel agents, may be considered.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.10.155

PubMed ID

  • 15365068

Additional Document Info

start page

  • 3720

end page

  • 5

volume

  • 22

number

  • 18